Efficacy of Robotic Bronchoscopy for Molecular Marker Analysis in Primary Lung Cancer
Clinical Lung Cancer · 2024-01 · 25 (1) · e11-e17
DOI: 10.1016/j.cllc.2023.10.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2024-01. Verfasst von Alejandra Yu Lee-Mateus und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville, FL. Hauptthemen laut MEDLINE: Lung Neoplasms, Robotic Surgical Procedures. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND: Molecular testing has become a more frequent necessity in NSCLC management. Using next-generation sequencing, multiple targets for therapy can be identified with small amounts of nuclear material. The authors evaluated the performance of robotic-assisted bronchoscopy in acquiring tissue that meets pre-analytic criteria for PD-L1 immunohistochemistry and/or next-generation sequencing. MATERIALS AND METHODS: Patients with a diagnosis of primary lung cancer identified through robotic bronchoscopy were retrospectively reviewed. Pathology reports were assessed for results of molecular testing and detection of programmed death-ligand 1 (PD-L1). An independent pathologist evaluated each specimen type (smears, cell block, tissue biopsy, and/or touch prep) to determine whether each tissue type would meet pre-analytic criteria for attempting next-generation sequencing and/or PD-L1 immunohistochemistry. RESULTS: Seventy-eight patients with primary lung were reviewed. By independent pathologic assessment of cytological smears, cell block, biopsy, and/or touch preparations, 72% of samples were found to be adequate for molecular and PD-L1 testing. Preanalytic adequacy (%) for next-generation sequencing (NGS) and PD-L1 staining was determined based on specimen type: cytological smear 48.6% for NGS; cell block 14.3% for NGS and 32.9% for PD-L1; biopsy 29.2% for NGS and 62.5% for PD-L1; and touch prep 61.4% for NGS. CONCLUSION: Robotic-assisted bronchoscopy yielded samples that met preanalytic criteria for molecular testing in 72% of cases. These results support the use of robotic-assisted bronchoscopy for both the diagnosis and molecular testing of early-stage lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville, FL.
- Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
- Department of Pathology, Mayo Clinic, Rochester, MN.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
- Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN; Department of Surgery, Division of Thoracic Surgery, Mayo Clinic, Rochester, MN. Electronic address: reisena…
Zitieren
APA
Yu Lee-Mateus, A., Sawal, N., Hartley, C., Edell, E., Vierkant, R. A., & Reisenauer, J. (2024). Efficacy of Robotic Bronchoscopy for Molecular Marker Analysis in Primary Lung Cancer. Clinical Lung Cancer, 25(1), e11-e17. https://doi.org/10.1016/j.cllc.2023.10.003
Vancouver
Yu Lee-Mateus A, Sawal N, Hartley C, Edell E, Vierkant RA, Reisenauer J. Efficacy of Robotic Bronchoscopy for Molecular Marker Analysis in Primary Lung Cancer. Clinical Lung Cancer. 2024;25(1):e11-e17. doi:10.1016/j.cllc.2023.10.003
BibTeX
@article{YuLeeMateus2024,
author = {Yu Lee-Mateus, Alejandra and Sawal, Naina and Hartley, Christopher and Edell, Eric and Vierkant, Robert A and Reisenauer, Janani},
title = {Efficacy of Robotic Bronchoscopy for Molecular Marker Analysis in Primary Lung Cancer},
journal = {Clinical Lung Cancer},
year = {2024},
volume = {25},
number = {1},
pages = {e11--e17},
doi = {10.1016/j.cllc.2023.10.003}
}
EUVIMED